A non-randomized pragmatic historically controlled trial evaluating the effectiveness and safety of a bedaquiline or a linezolid-based short regimen for rifampicin-resistant tuberculosis
The ShORRT strategy with a nine-month BDQ- or LZD-based regimen supports the efficacy of shorter all-oral regimens for the treatment of RR-TB and presents real-world data from schemes without bedaquiline, nitroimidazole, or injectables.
Authors
- Joan Martínez‐Campreciós (ORCID: https://orcid.org/0000-0002-8899-8447)
- Elena Sulleiro (ORCID: https://orcid.org/0000-0002-9783-6060)
- Sandra Aixut
- M. Nicolau
- Rafael Terán
- Adriano Zacarías
- Israel Molina (ORCID: https://orcid.org/0000-0001-6642-7515)
- Juan Espinosa‐Pereiro (ORCID: https://orcid.org/0000-0002-7238-8337)
- María Luisa Aznar
- Manuel Ramos (ORCID: https://orcid.org/0000-0001-7264-8234)
- Arlete Nindia
- Teresa Tórtola
- Adrián Sánchez-Montalvá
Institutions
- Instituto de Salud Carlos III (ES)
- Hospital Nossa Senhora das Graças (BR)
- Centro de Investigación Biomédica en Red (ES)
- National Center for Tuberculosis and Lung Disease (GE)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- Journal of Infection
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1016/j.jinf.2024.106291
- Citations
- 1
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Ministerio de Ciencia e Innovación
- Instituto de Salud Carlos III